Which drug works better after infant valve surgery? new study compares mirabegron and oxybutynin
NCT ID NCT07668232
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This study looked at two drugs, mirabegron and oxybutynin, in 52 children over age 3 who had surgery for posterior urethral valves. The goal was to see which drug better improves bladder and kidney function and reduces urinary tract infections. Researchers also checked safety by monitoring blood pressure and heart rate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Mirabegron and oxybutynin
- What this could lead to
- If successful, this could show that mirabegron is a safer or more effective option than oxybutynin for managing bladder function after valve surgery in children.
- What could go wrong
- This is a small, completed trial with only 52 participants, so results may not apply to all children. The study compares two existing drugs, so no major breakthrough is expected.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POSTERIOR URETHRAL VALVE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qina University hospital, South Valley University Hospital
Qina, South Valley, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.